|
2016
|
Invention
|
Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors.
Provided herein are ... |
|
2015
|
Invention
|
3,5-diaminopyrazole kinase inhibitors. Provided herein are 3,5-diaminopyrazoles, for example, com... |
|
|
Invention
|
2,5-disubstituted arylsulfonamide ccr3 antagonists.
Provided herein are 2,5-disubstituted arylsu... |
|
|
Invention
|
Isotopically enriched arylsulfonamide ccr3 antagonists. Provided herein are isotopically enriched... |
|
2014
|
Invention
|
Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors. Provided herein are p... |
|
|
Invention
|
Arylsulfonamide ccr3 antagonists.
Provided herein are arylsulfonamides that are useful for modul... |
|
2013
|
Invention
|
2,5-disubstituted arylsulfonamide ccr3 antagonists. Provided herein are 2,5-disubstituted arylsul... |
|
|
Invention
|
2-phenoxy- and 2-phenylsulfonamide derivatives with ccr3 antagonistic activity for the treatment ... |
|
|
Invention
|
Arylsulfonamide ccr3 antagonists. Provided herein are arylsulfonamides that are useful for modula... |
|
2011
|
Invention
|
Salts of arylsulfonamide ccr3 antagonists. Provided herein are arylsulfonamide salts, e.g., a sal... |
|
|
Invention
|
Salts of arylsulfonamide ccr3 antagonists.
Provided herein are arylsulfonamide salts, e.g., a sa... |
|
2010
|
Invention
|
Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immu... |
|
2005
|
Invention
|
Regulation of human p2y1-like g protein-coupled receptor.
Reagents which regulate human P2Y1-lik... |
|
2004
|
Invention
|
Regulation of kinase, regulated in copd kinase (rc kinase). Reagents which regulate human RC Kina... |
|
2003
|
Invention
|
Regulation of human p2y15 g protein-coupled receptor.
Reagents which regulate human P2Y15 G prot... |
